The Purdue Institute for Cancer Research (PICR) connects with the Austin, Texas community in two events that put Purdue’s scientific leadership on full display and open a genuine dialogue about where cancer research is headed next.
Andrew Mesecar, the Robert W. Miller Director of the PICR and Walther Professor of Cancer Structural Biology, traveled to Austin to lay out how Purdue researchers are reshaping the landscape of cancer detection and treatment. The visit took two forms: a public lecture hosted by the Austin Forum on Technology & Society, and an intimate “Dinner with the Director” organized by the PICR alongside the Purdue Alumni Club of Austin.
The events drew Boilermakers, technology leaders, scientists and community members into the same room — and into the same conversation — about the science powering the next generation of cancer therapies, the necessity of working across disciplines, and the outsized role that research universities play in moving discoveries from bench to bedside.
Public lecture spotlights the technologies rewriting cancer research
Mesecar’s presentation, “Emerging Technologies in the Fight Against Cancer: Targeted Therapies, Personalized Medicine and AI,” delivered at Austin Community College’s Rio Grande campus, was less a survey of the field than an argument for urgency and a cause for optimism.
He traced how advances in technology are simultaneously deepening our understanding of cancer’s biology and accelerating the pace at which new therapies and diagnostics reach patients. Anchoring the discussion in real outcomes, Mesecar highlighted three FDA-approved drugs and imaging agents developed by institute researchers in recent years (Pluvicto®, Locametz® and CYTALUX®) as evidence that the work happening at Purdue translates. He then turned to what’s coming: liquid biopsy technologies capable of detecting cancer earlier and less invasively; AI and machine learning tools that can find signal in biological datasets too complex for conventional analysis; and personalized medicine approaches that match therapies to the specific molecular profile of a patient’s disease.
Running through the entire presentation was a case for Purdue’s particular strengths as a research environment. With institute members drawn from chemistry, engineering, veterinary medicine, computer science and beyond, the PICR operates as something rarer than a center — it functions as a convergence point for disciplines that don’t usually share a corridor, let alone a research agenda.
Alumni dinner deepens the conversation
If the public lecture made the science accessible, “Dinner with the Director” made it personal.
The PICR hosted the gathering in partnership with the Purdue Alumni Club of Austin, which counts more than 4,000 Purdue alumni among the region’s ranks. What followed was less a formal program than an extended exchange. Alumni and community members sharing their own experiences with and concerns about cancer, pressing Mesecar on how discoveries actually move from the laboratory to the clinic and asking where they fit into the efforts to accelerate that process.
Mesecar spoke to the institute’s standing as one of only seven National Cancer Institute (NCI)-designated basic science cancer centers in the United States. The designation not only signals institutional excellence but a specific commitment to foundational research: understanding, at the most fundamental level, how cancer begins, how it evolves, and how it might be stopped before it advances. He also spoke to areas where Purdue is doing distinctive work: comparative oncology, which draws insights from naturally occurring cancers in animals to illuminate human disease, and precision medicine and early detection technologies that are closing the gap between diagnosis and effective interventions.
Strengthening ties between Purdue and Austin
Austin is not a random stop. It is a city defined by its appetite for technological innovation and home to an active Purdue alumni network.
The PICR’s engagement there reflects a deliberate recognition that the conversations shaping the future of cancer research take place both within the university setting and far beyond the confines of campus. By meeting directly with community members, alumni and technology leaders, the PICR is doing something that research institutions don’t always do well: making the case, in plain terms, for why basic science matters. The work underway at Purdue, from structural biology to computational modeling, is not abstract. It is the foundation on which better treatments are built, and the PICR is committed to ensuring that the people who care most about those treatments understand exactly what that work entails.
Your support fuels the fight against cancer